Black Diamond Therapeutics Files Definitive Proxy Statement
Ticker: BDTX · Form: DEF 14A · Filed: Apr 18, 2025 · CIK: 1701541
| Field | Detail |
|---|---|
| Company | Black Diamond Therapeutics, Inc. (BDTX) |
| Form Type | DEF 14A |
| Filed Date | Apr 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: BDTX
TL;DR
BDTX proxy filed, shareholder meeting June 12. Governance stuff.
AI Summary
Black Diamond Therapeutics, Inc. filed its definitive proxy statement on April 18, 2025, for its annual meeting on June 12, 2025. The company, previously known as Aset Therapeutics, Inc. until March 21, 2017, is involved in the biological products sector. The filing is related to the company's governance and shareholder matters.
Why It Matters
This filing outlines the agenda for Black Diamond Therapeutics' upcoming shareholder meeting, including any proposals or director elections that could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain new financial or strategic information that would immediately impact stock price.
Key Numbers
- 0001701541 — Central Index Key (Unique identifier for Black Diamond Therapeutics, Inc.)
- 001-39200 — SEC File Number (SEC filing number for Black Diamond Therapeutics, Inc.)
Key Players & Entities
- Black Diamond Therapeutics, Inc. (company) — Registrant
- Aset Therapeutics, Inc. (company) — Former company name
- 20250418 (date) — Filing date
- 20250612 (date) — Meeting date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information regarding the company's annual meeting, including any proposals to be voted on and director nominations.
When is the shareholder meeting scheduled?
The shareholder meeting is scheduled for June 12, 2025.
What was Black Diamond Therapeutics' former name?
Black Diamond Therapeutics, Inc. was formerly known as Aset Therapeutics, Inc.
What is the company's primary business sector?
The company's Standard Industrial Classification is Biological Products (No Diagnostic Substances) [2836].
Where is Black Diamond Therapeutics headquartered?
Black Diamond Therapeutics, Inc. is headquartered in Cambridge, MA, with its business address at One Main Street, 14th Floor, Cambridge, MA 02142.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 18, 2025 regarding Black Diamond Therapeutics, Inc. (BDTX).